ISPOR 18 th Annual European Congress, Milan, Italy, 7-11 November, 2015. POSTER CODE PHP28
CONCLUSIONS
• EAP policies are evolving fast, signaling high interest, and will likely be increasingly important. Compared to a previous assessment (2012), we observed:
• In countries open to EAP, there is a trend to strengthen the regulation and avoid the marketing use of EAP
• In countries with EAP restrictions, the process has been developing towards a more structured and faster process
• In all countries, there is a strong recognition of EAP value to support patients who are poorly serviced with exisiting treatment alternatives
• It is yet to be seen how updates will affect the market access condition of products undergoing EAP but the trend is to open up to EAPs thus more medicines will go through the EAPs that exist
• Pharmaceutical companies need to make sure that when they are planning to seek regulatory approval to enter an EAP, they also capitalise on the opportunity to shape market access conditions and pricing and reimbursement for the medicine postmarket authorisation. Companies should closely monitor EAP regulations and their impact on market access as it is a dynamic environment, with potential downstream implications for pricing and access, as well as RWD investments
RESULTS (continuation)
• Denmark, Norway, Spain, and Austria also provide good opportunities for EAPs. EAP processes are in line with EU regulations on Compassionate Use, and pricing and reimbursement are possible, albeit conditional. In Italy, price is set freely and reimbursement is full but the bureaucracy is a barrier to implementation and inclusion may be difficult. Outside of the EU, Canada, Israel, Australia, and New Zealand have straightforward processes and pricing and reimbursement are conditional
III. Countries with +2
• EAP sales are not possible in Germany, Sweden CUP, Brazil, and Turkey. Sales are possible for Sweden Licensing Procedure (LP) and reimbursement is assured but this is currently under review. In LP, it is unclear how the price is set but it may be regulated by the Dental and Pharmaceutical Benefits Agency (TLV). In Portugal, Switzerland, South Africa, and South Korea, the legislation is not comprehensive and there is not a clear process to gain approval for an EAP
IV. Countries with +1
• In the UK and Belgium, both processes are relatively new (2014) and are yet to be tested.
These two programmes are also noted to have steep EAP administration fees, in addition to the internal resource costs and costs of setting up a registry
• The UK should however be put into careful context as it is an important major market with global influence where future potential is substantial. On the same lines, the score (+) for Belgium is only in the interim as the process is set to become clearer in the next few months
• For Poland, an official CUP policy does not exist in the country. Import Docelowy relates more to the import of unlicensed drugs in Poland that alludes to an Early Access policy EAP considerations by country were ranked according to the following criteria:
• Clarity of the process -if the guidelines, legislation, official websites are comprehensive regarding the process and requirements • A plus sign (+) connotes that the process is clear and a minus sign (-) connotes the lack of clarity in the process • Ease of implementation -if implementation barriers are noted such as, but not limited to, administrative requirements that are time and resource-limiting, the process is complicated, or if it is new and untested, etc.
• A plus (+) sign connotes no major difficulties in implementation and a minus (-) sign connotes barriers are evident • Possibility of revenues -establish an initial price, and obtain reimbursement • A double plus sign (++) connotes EAP sales, free pricing & reimbursement are possible; a single plus sign (+) connotes EAP sales are possible but price is not freely set or reimbursement is conditional; a minus (-) sign connotes EAP sales are not possible 
